Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article Swaminathan P. Iyer and colleagues authored on LinkedIn:

“New study spearheaded by researchers from MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center on CTX130, a CAR T-cell therapy for relapsed/refractory T-cell lymphoma, has been completed across the USA, Australia, and Canada. The phase 1 trial included 39 heavily pre-treated patients.

Key Findings:

Safety: Manageable, with cytokine release syndrome being the most common side effect (67% of patients).
Efficacy: 46.2% of patients showed an objective response, with improved results at higher doses (51.6%).

This study indicates that off-the-shelf CAR T cells could be a viable option. Next, CTX131, an enhanced version, is in development.”

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Authors: Swaminathan P. Iyer et al.

Yan Leyfman

Yan Leyfman: Off-the-shelf CAR T cells could be a viable option for R/R T-cell Lymphoma